TherapeuticsMD (TXMD) Net Income Growth (3y) (2013 - 2026)
TherapeuticsMD (TXMD) Net Income Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.88 Bn | 87.01 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 51.28% |
| 3 | Zoetis | 32.31 Bn | 30.37 Bn | 1.62 Bn | 2.94% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | -62.58% |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn | 4.50% |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn | -7.75% |
| 8 | Neurocrine Biosciences | 17.92 Bn | 16.61 Bn | 800.70 Mn | 66.11% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | -17.90% |
| 10 | TherapeuticsMD | 284,239.99 | -8.13 Mn | - | 81.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 81.64% |
| Dec 31, 2025 | -26.00% |
| Sep 30, 2025 | 26.14% |
| Jun 30, 2025 | -96.39% |
| Mar 31, 2025 | 91.83% |
| Dec 31, 2024 | -85.99% |
| Sep 30, 2024 | 90.40% |
| Jun 30, 2024 | 90.21% |
| Mar 31, 2024 | 26.03% |
| Dec 31, 2023 | 26.32% |
| Sep 30, 2023 | 60.94% |
| Mar 31, 2023 | 71.67% |
| Dec 31, 2022 | 37.36% |
| Sep 30, 2022 | 23.46% |
| Jun 30, 2022 | 62.64% |
| Mar 31, 2022 | 7.62% |
| Dec 31, 2021 | 48.48% |
| Sep 30, 2021 | -10.02% |
| Jun 30, 2021 | -8.69% |
| Mar 31, 2021 | -17.30% |